Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans-Reference-Cited by-同舟云学术

Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans

Published:2020-05-19 Issue:19 Volume:323 Page:1972
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Chambers James D.¹,Lai Rachel C.¹,Margaretos Nikoletta M.¹,Panzer Ari D.¹,Cohen Joshua T.¹,Neumann Peter J.¹

Affiliation:

1. Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/articlepdf/2766151/jama_chambers_2020_ld_200012.pdf

Reference5 articles.

1. Why are biosimilars not living up to their promise in the US?;Zhai;AMA J Ethics,2019

2. Biologics Price Competition and Innovation (BPCI) Act.;Fed Regist,2010

3. Specialty drug coverage varies across commercial health plans in the US.;Chambers;Health Aff (Millwood),2018

4. Prescription drug cost sharing: associations with medication and medical utilization and spending and health.;Goldman;JAMA,2007

5. US Food and Drug Administration. Biosimilars. Published September 23, 2019. Accessed January 30, 2020. https://www.fda.gov/drugs/therapeutic-biologics-applications-bla/biosimilars

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. US Commercial Plans Increase Choice Of Biosimilar And Originator Products; Market Net Prices Decrease;Health Affairs;2024-09-01

2. Patterns of Infliximab Biosimilar Uptake for Medicare, Medicaid, and Private Insurance from 2016 to 2022;Arthritis & Rheumatology;2024-08-13

3. Mapping Health Technology Assessment Agency Approaches for Biosimilar Value Assessment: An ISPOR Special Interest Group Report;Value in Health;2024-05

4. Real-World Clinical Outcomes of Bevacizumab-awwb Biosimilar versus Bevacizumab Reference Product in Patients with Metastatic Colorectal Cancer;BioDrugs;2023-09-25

5. An international comparative analysis and roadmap to sustainable biosimilar markets;Frontiers in Pharmacology;2023-08-24